Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21331820 | 0.88 | ROCK2 (0.64) | ROCK2 | |
| SCHEMBL30788622 | 0.86 | ROCK2 (0.62) | ROCK2 | |
| SCHEMBL12994018 | 0.85 | ROCK2 (0.52) | ROCK2 | |
| SCHEMBL14716768 | 0.82 | ROCK2 (0.58) | ROCK2 | |
| SCHEMBL30714841 | 0.82 | ROCK2 (0.58) | ROCK2 | |
| SCHEMBL30956271 | 0.82 | ROCK2 (0.58) | ROCK2 | |
| SCHEMBL29972662 | 0.82 | ROCK2 (0.51) | ROCK2 | |
| SCHEMBL12994019 | 0.82 | ROCK2 (0.49) | ROCK2 | |
| SCHEMBL21331803 | 0.81 | CA1 (0.40) | ROCK2CA1CA2CA7CA9 | |
| SCHEMBL30785325 | 0.81 | ROCK2 (0.57) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634171-A1 | PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE | F. Hoffmann-La Roche AG (CH) | 2025-10-22 | — | — | EP | claimed |
| US-20250313551-A1 | PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE | HOFFMANN-LA ROCHE INC. (US) | 2025-10-09 | — | — | US | claimed |
| CN-119978004-A | Water-stable 2-pyridine inner salt boron reagent, preparation method thereof and application thereof in coupling reaction | 苏州大学 | 2025-05-13 | — | — | CN | claimed |
| WO-2024126634-A1 | PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-20 | — | — | WO | claimed |
| WO-2023102255-A1 | PEPTIDE-ENCODED LIBRARIES OF SMALL MOLECULES FOR DE NOVO DRUG DISCOVERY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-08 | — | — | WO | claimed |
| CN-114085213-B | Preparation method of ARV-471 | 苏州国匡医药科技有限公司 | 2022-03-25 | — | — | CN | claimed |
| WO-2026105055-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY, INC (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4743462-A1 | COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS | Tay Therapeutics Limited (GB) | 2026-05-20 | — | — | EP | disclosed |
| US-12630452-B2 | Electrohydromodulating process for recovering nutrients, mineralizing organics, and inactivating pathogens in wastewater | UNIVERSITY OF MIAMI (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260132140-A1 | IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4735430-A1 | MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2022072634-A1 | BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022069520-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-04-07 | — | — | WO | disclosed |
| EP-3976584-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2022066734-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| CN-114085213-B | Preparation method of ARV-471 | 苏州国匡医药科技有限公司 | 2022-03-25 | — | — | CN | disclosed |
| WO-2022051567-A1 | SUBSTITUTED PYRIDO[2,3-B]PYRAZINONES AND REUATED COMPOUNDS AND THEIR USE IN TREATING MEDICAU CONDITIONS | Ikena Oncology, Inc. (US) | 2022-03-10 | — | — | WO | disclosed |
| CN-114085213-A | Preparation method of ARV-471 | 苏州国匡医药科技有限公司 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | ROCK2 1784/4885CA1 2874/4885CA2 1083/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | ROCK2 2338/4885CA1 2208/4885CA2 1088/4885 |
| US-20260132140-A1 | IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS | CHEK1, CHEK2, BUB1 | ROCK2 2676/4885CA1 1426/4885CA2 669/4885 |
| US-20250313551-A1 | PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE | NQO2, SDHA, NDUFS3 | ROCK2 2848/4885CA1 3931/4885CA2 3419/4885 |
| US-12630452-B2 | Electrohydromodulating process for recovering nutrients, mineralizing organics, and inactivating pathogens in wastewater | CASR, ORAI1, ANO1 | ROCK2 1633/4885CA1 77/4885CA2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.